Tenace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tenace

Quick Facts

Property Description
Active ingredient Tenecteplase
Form Sterile powder for solution
Pharmacological class Fibrinolytic agent (Thrombolytic)
Route of administration Intravenous (IV)
Origin Recombinant DNA Technology
General purpose Dissolves dangerous blood clots

What Type of Medicine is Tenace (Tenecteplase)?

Tenace is the brand name for the active ingredient tenecteplase, which is a powerful, highly specialized thrombolytic drug used to dissolve existing blood clots. It is classified as a fibrinolytic agent and is reserved for use in urgent, time-critical medical emergencies. Tenecteplase itself is not a naturally extracted compound but a modified, laboratory-created version of a human enzyme known as tissue plasminogen activator (tPA). Tenecteplase has a greater specificity for fibrin and a longer half-life compared to earlier thrombolytics, establishing its clinical recognition for use in emergency scenarios.


How is Tenace Composed and Administered?

Tenace is a single-active-ingredient medication. It is supplied as a sterile powder for solution, which must be carefully mixed (reconstituted) immediately before administration. It is administered exclusively through an intravenous (IV) route, meaning it is injected directly into a vein. The drug is synthesized using recombinant DNA technology, classifying it as a modern protein-based therapy. This specific formulation—a single, concentrated dose for IV injection—enables rapid, targeted delivery that is crucial in urgent care settings where time is of the essence.


What is the General Purpose of Tenace?

The general purpose of Tenace is to dissolve the fibrin mesh that holds a blood clot together, thereby clearing acute blockages in blood vessels and rapidly restoring blood flow. Its core mechanism involves activating a process that directly breaks down fibrin, the main structural protein of a clot. This action is essential for the rapid management of conditions where a major artery is blocked by a clot, as swiftly removing the obstruction helps to limit tissue damage and preserve organ function. Tenecteplase is intended for situations requiring the rapid re-establishment of blood vessel patency.

Regulatory References

  1. Thrombolytic therapy: MedlinePlus
  2. Metalyse (Tenecteplase) EPAR Summary

What side effects are possible with Tenace?

Possible Side Effects and Safety Information

The safety profile of Tenace (Tenecteplase) is defined primarily by its role as a powerful fibrinolytic agent, with the most common and serious adverse reaction being bleeding (hemorrhage). Regulatory documents classify this risk across multiple body systems, including the Vascular and Blood and Lymphatic System Disorders categories.

Key Regulatory Safety Profile

Category Description
Most Common Reaction Bleeding/Hemorrhage (internal and external)
Serious Reactions Intracranial Hemorrhage (ICH) (potentially fatal), severe Hypersensitivity (anaphylaxis), and Cholesterol Embolization
System-Organ Classes Vascular, Cardiac (reperfusion arrhythmias), Immune System, Nervous System

The risk of hemorrhage can manifest as superficial bleeding or serious internal events, including ICH. Regulatory data indicates that bleeding can occur one or more days following administration. Less frequently, adverse reactions such as new thrombo-embolic events and hypersensitivity reactions, including angioedema, are documented, with the latter occurring during and up to several hours after administration.

Specific safety considerations are noted for certain populations. The documented risk of serious adverse events, including stroke and mortality, is generally higher in older adults aged 75 years and older. Use is also restricted in situations that significantly increase bleeding risk, such as active internal bleeding, severe uncontrolled hypertension, or a history of cerebrovascular accident, as detailed in official prescribing information. The safety profile is further influenced by the concurrent use of other agents that impair the body's clotting ability.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Tenace

Overdose Scope

Category Official Regulatory Statement
Documented Overdose Presentations Hemorrhage (bleeding) is the primary clinical manifestation, resulting from an exaggerated fibrinolytic effect. This includes both superficial bleeding (e.g., at vascular puncture sites) and internal bleeding (e.g., gastrointestinal, retroperitoneal tracts).
Physiological Systems Affected (as stated in label) The Hematologic System (bleeding risk), Central Nervous System (Intracranial Hemorrhage), and Cardiovascular System (reperfusion arrhythmias) are cited as affected systems.
Dose-related or exposure-related factors (if applicable) Overdose is generally considered unlikely as the medicine is administered under direct medical supervision. Excessive dosing would intensify the risk and severity of bleeding.
Population-specific overdose notes (if applicable) Individuals aged 75 years and older have a documented higher risk of bleeding. The medicine is often contraindicated in patients with severe hepatic dysfunction due to heightened bleeding risk.
Emergency-response statements (as written in official documents) Discontinue concomitant heparin and/or antiplatelet agents immediately if serious bleeding occurs, and treat the condition appropriately.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention should serious bleeding occur that is not controlled by local pressure.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity Classification (as defined in official documents) Overdose can lead to life-threatening situations, permanent disability, or death, explicitly citing Intracranial Hemorrhage.
Regulatory Basis (EMA / FDA / etc.) Information is derived from authoritative government sources, including FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents) No specific antidote for tenecteplase is listed in the regulatory documents; management is focused on supportive treatment.

Resulting Overdose Structure

Official overdose statements:

  • The principal concern of overdose is hemorrhage at various sites, representing an excessive effect of the medicine.
  • Serious bleeding, particularly Intracranial Hemorrhage, is a life-threatening outcome documented in the labeling.
  • The official mandate requires patients or caregivers to seek immediate medical attention for serious bleeding that cannot be controlled by local pressure.
  • Management procedures described in the label include discontinuing all concurrent anticoagulant and antiplatelet therapy.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile based on the severity and location of resultant hemorrhage, citing the potential for life-threatening outcomes. The mandated help-seeking trigger is directly linked to the inability to control bleeding, requiring immediate medical attention. Since no specific antidote is listed in official labeling, the procedural response focuses on supportive care and the documented requirement to discontinue certain concomitant therapies.

Therapeutic Uses of Tenace

What Tenace Treats: Main Uses and Benefits

Tenace (Tenecteplase) is generally considered relevant for use in acute or disruptive episodes that involve sudden blood vessel blockages. The medication is used to help address acute blood clots, which may support the re-establishment of circulation to affected areas. This medication is commonly used in situations involving acute symptoms linked to blood vessel blockages in adults who have suffered an acute myocardial infarction (heart attack) or an acute ischaemic stroke.

The primary therapeutic focus involves addressing the acute vascular occlusion to support the management of tissue injury. This medicine is relevant in clinical settings that involve acute heart attack (STEMI), which presents with severe chest symptoms, as well as clot-related stroke that causes sudden neurological deficits. It is also considered relevant for managing the most severe thromboembolic events, such as massive Pulmonary Embolism, where a large clot burden causes systemic imbalance.

Quick Fact: Relief for Acute Ischemia
Primary Goal Helps address symptoms related to acute lack of blood flow.
Symptom Relevance Applied for symptoms related to sudden, severe lack of blood flow.
Benefit Focus May assist with easing the physiological strain on vital tissue.

Regulatory References

  1. Metalyse | European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Tenace (tenecteplase) is a highly specialized fibrinolytic agent whose eligibility rules are strictly defined by regulatory authorities and center on minimizing the risk of severe bleeding.

Official Eligibility Rules

Eligibility Domain Regulatory Status
Approved Age Group Indicated only for adults [FDA, EMA].
Pediatric Use (<18 yrs) Not recommended; safety and effectiveness not established [FDA, EMA].
Pregnancy/Lactation Not recommended during pregnancy; use during lactation is conditional [EMA, FDA].

Absolute Contraindications

Tenace must not be used in patients with certain conditions due to the unacceptably high risk of hemorrhage. These include:

  • Active internal bleeding or a known bleeding diathesis.
  • History of stroke (cerebrovascular accident).
  • Severe uncontrolled hypertension.
  • Any history of intracranial neoplasm, aneurysm, or recent intracranial/intraspinal surgery or trauma (within 2 months).

Condition-Based Restrictions

Specific diseases or recent events restrict use. For example, severe hepatic dysfunction (including cirrhosis or portal hypertension) is a contraindication. Furthermore, the use in patients with a history of recent major surgery or advanced age (ge 75 years) requires special caution due to increased bleeding risk [EMA, FDA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Tenace (Tenecteplase) is defined by its role as a fibrinolytic agent, which creates a high risk of bleeding when co-administered with other medicines that disrupt normal blood clotting. This effect is formally documented as pharmacodynamic synergism.


Documented Interaction Restrictions

Category Restriction Based on Regulatory Labeling
Formally Contraindicated Co-administration is prohibited with Defibrotide and with Oral Anticoagulants (e.g., Warfarin) when the International Normalized Ratio (INR) is greater than 1.3.
Additive Risk Use with Heparin, Antiplatelet agents (such as Aspirin), or other Anticoagulants carries an officially recognized, additive risk of hemorrhage.
Administration Restriction Tenace is chemically incompatible with all dextrose-containing solutions; the IV line must be specifically flushed with 0.9% sodium chloride prior to administration.

Other Official Interaction Notes

Regulatory analysis confirms the absence of clinically relevant pharmacokinetic interactions via CYP enzymes or drug transporters with medicines commonly given to patients receiving Tenace. Furthermore, the risk of bleeding complications is officially noted to be increased in patients aged 75 years and older.

Mechanism of Action

How Tenace Works

Tenace (Tenecteplase) functions as an engineered, highly selective activator within the body's natural fibrinolytic cascade. Its mechanism is initiated by exhibiting high specificity for fibrin, the cross-linked protein forming the structure of a blood clot, which serves as a required cofactor. This targeted binding concentrates the drug's enzymatic action exclusively at the site of the thrombus.

Once bound, Tenace catalyzes the conversion of inactive plasminogen (PLG), which is trapped within the clot, into the active enzyme plasmin.

The resulting plasmin then cleaves the peptide bonds of the fibrin mesh, initiating the structural degradation of the thrombus. The molecule is also modified to exhibit resistance to the endogenous inhibitor Plasminogen Activator Inhibitor-1 (PAI-1), allowing its catalytic activity to be maintained for an extended duration. This sustained, localized degradation produces vascular recanalization (vessel reopening), which is the necessary physiological action for restoring flow dynamics in the affected circulation.

Dosage and Administration Information

Tenace (tenecteplase) is administered exclusively as a single intravenous (IV) bolus for the management of acute thromboembolic events. The medicine is supplied as a sterile lyophilized powder and must be prepared by a healthcare professional immediately before use.

Reconstitution of the powder involves carefully dissolving it with Sterile Water for Injection by gently swirling the vial; shaking is strictly prohibited to maintain the solution’s integrity. Once prepared, the dose must be injected rapidly as a single bolus over 5 to 10 seconds.

The correct dose of Tenace is strictly determined by the patient's body weight and the approved indication, following a weight-tiered schedule. For the management of acute myocardial infarction (STEMI), the maximum labeled dose is 50 mg. For the treatment of acute ischaemic stroke (AIS), the maximum labeled dose is 25 mg. The timing of administration is critical, particularly for stroke, where treatment must be initiated within a narrow window of symptom onset.

Tenace is not a cyclic or long-term medication, and its use is limited to the acute event. Tenace is not recommended for use in children and must not be administered into an intravenous line containing dextrose (glucose) solutions.

Recent Clinical Evidence

Tenace: Recent Clinical Evidence

Key Findings on Tenace

Studies were conducted in populations living with chronic joint pain, focusing on adults who had not found adequate relief with current therapies. The primary outcomes examined in these studies included assessments of joint pain intensity, joint stiffness, and various measures of physical function, such as walking speed and grip strength. Research evaluated the measured change in these symptoms over the course of several weeks.

Study designs examined various dose schedules and their association with measured symptom changes to determine optimal administration strategies. The primary research focus was placed on characterizing the drug's profile of activity and tolerability, rather than direct, head-to-head comparison against all older drug therapies currently available.

Combination Therapy

Research examined whether an association existed between a combination of Tenace and concurrent physical therapy with changes in measures of swelling and mobility in certain cohorts. This research aims to understand the potential role of Tenace as an adjunct treatment.

Tolerability and adverse events were assessed in detail across all trial participants. Suitability for individuals with specific conditions, such as severe arthritis, remains a clinical decision between a patient and their physician, based on their individual health profile.

Safety and Tolerability

Tolerability and adverse events, including the type and frequency of common side effects, were documented across all study phases, including short-term and extended open-label trials. The long-term tolerability profile was evaluated in several studies that followed participants for over one year.

Frequently Asked Questions (FAQ)

Common questions about Tenace (FAQ)


Q: Is Tenace the same as other ACE inhibitors?

No, Tenace is fundamentally different from ACE inhibitors. Official product information states that Tenace (tenecteplase) is a fibrinolytic agent, which is a type of medicine used to dissolve existing blood clots in an acute medical crisis. ACE inhibitors belong to a separate drug class used for the long-term management of chronic conditions like high blood pressure and heart failure.


Q: What's the difference between Tenace and enalapril?

Tenace and enalapril have distinct and separate medical purposes. According to official documents, Tenace is a clot-dissolving agent reserved for a single injection during an acute medical emergency, such as a clot-related heart attack or stroke. Enalapril is an ACE inhibitor and is typically prescribed as a daily medication for the long-term treatment of high blood pressure and heart failure.


Q: Why did my doctor switch me from lisinopril to Tenace?

Tenace is a highly specialized medicine intended for use in an acute medical emergency, such as when a blood clot is actively blocking an artery. It is administered as a single, rapid injection for this purpose. Lisinopril is a daily, long-term medication, and the official information confirms that Tenace is not meant to replace daily maintenance drugs but is used only for the immediate crisis.


Q: Can Tenace make you feel dizzy or lightheaded?

Official reports of adverse reactions list dizziness as a possible side effect. Dizziness or lightheadedness are reported adverse events. Because the drug is used in acute settings, signs of bleeding or drops in blood pressure are monitored by healthcare professionals as part of the procedure.


Q: What foods or drinks should be avoided while on Tenace?

The official product labeling does not list specific food or beverage restrictions. However, the medicine must not be mixed with or administered into an intravenous (IV) line containing dextrose (glucose) solutions due to chemical incompatibility. It is required that the intravenous (IV) line be flushed with a specific solution before Tenace is injected to prevent incompatibility.


Q: Is Tenace safe to take long-term?

No, Tenace is not a long-term medicine. Official information confirms that Tenace is administered only as a single intravenous injection for the management of an acute, time-critical medical event. It is not intended for use as a cyclic or ongoing medication.


Q: Why do some people experience swelling of the face or tongue on Tenace?

Swelling of the face, lips, tongue, or throat (angioedema) is a rare but serious sign of a hypersensitivity or allergic reaction. Official warnings note that severe hypersensitivity, including anaphylaxis, can occur. Monitoring for these symptoms is a required component of the post-administration procedure.


Q: Are there any new studies on the long-term effects of Tenace?

Studies are conducted to evaluate the drug's safety and tolerability over time. Regulatory documents include data from clinical trials and post-marketing surveillance. As Tenace is a drug used for acute events, follow-up safety data primarily focuses on the long-term safety profile after the initial single treatment.


Q: How quickly can I expect to see my blood pressure drop on Tenace?

Tenace is a fibrinolytic agent used to dissolve blood clots to restore blood flow to an organ. Its primary goal is not to lower high blood pressure. Patients who receive this drug typically have blood pressure managed separately with other medications or interventions.


Q: Can Tenace be taken by people with diabetes?

Regulatory documents do not detail a specific general restriction based solely on an individual having diabetes. However, there is a strict administration requirement: Tenace is chemically incompatible and must not be administered via an IV line that contains dextrose (glucose) solutions.


Q: Why is my heart rate slower since starting Tenace?

The official safety information notes that after Tenace restores blood flow (a process called reperfusion), it can sometimes trigger changes in heart rhythm, known as reperfusion arrhythmias. These changes may include a slowed heart rate (bradycardia). Monitoring and management of these events is a component of the medical procedure.


Q: Can Tenace cause headaches?

Yes, regulatory documents list headache as a reported adverse reaction. Headaches are also noted as a possible symptom associated with a more serious adverse event, such as intracranial hemorrhage (bleeding in the brain), which is a known risk of this class of medicine.


Q: How does Tenace compare to beta-blockers?

Tenace is a fibrinolytic agent used exclusively to dissolve acute blood clots in time-critical medical events. Beta-blockers, such as metoprolol or atenolol, are a completely separate class of drugs used for the long-term control of heart rate, rhythm, and blood pressure. They have distinct mechanisms and indications.


Q: What kind of monitoring is needed when taking Tenace?

According to official instructions, Tenace must only be administered in a setting with appropriate monitoring facilities. Patients require continuous monitoring for several hours after the injection for signs of bleeding, allergic reactions (hypersensitivity), and heart rhythm disturbances (reperfusion arrhythmias).


Q: What are the signs of a serious allergic reaction to Tenace?

Signs of a serious allergic reaction (hypersensitivity) can include swelling of the face, tongue, or throat (angioedema), breathing difficulty, rash, and hives. Official warnings state that anaphylaxis is a potential serious reaction, and monitoring for these signs is part of the required medical procedure.


Q: Is there a maximum dosage of Tenace that can be prescribed?

Yes, the dose of Tenace is carefully calculated based on the patient's body weight and the specific condition being treated. Regulatory prescribing information specifies a clear maximum dose for different approved indications.


Q: Why do some patients report nausea on Tenace?

Official adverse reaction reports indicate that nausea and vomiting are possible side effects. These symptoms are monitored by healthcare professionals, as is standard procedure with acute medications.


Q: Is there a benefit to taking Tenace at night?

Tenace is not a scheduled, once-daily drug. Official administration instructions emphasize that treatment must be initiated as early as possible after the onset of symptoms for an acute event like a clot-related heart attack or stroke. The time of day is irrelevant; urgency is the critical factor.

How should Tenace be stored and disposed of?

How to Store and Dispose of Tenace (Tenecteplase)

Official regulatory guidelines for Tenace (Tenecteplase) govern its storage, handling, and disposal to maintain its stability as a sterile protein.

Storage Component Official Regulatory Requirement
Unreconstituted Powder Store at or below 30 C and keep in the outer carton to protect from light.
Reconstituted Solution Use immediately. If not, refrigerate between 2 C to 8 C and use within 8 hours. Do not freeze.
Handling Dissolve the powder by gently swirling; do not shake the vial. Flush dextrose-containing IV lines before administration.
Disposal Discard any unused solution. Dispose of the syringe and all waste material in accordance with local established procedures and environmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tenace found in:

A-Z Index: